Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A.

Nat Med. 2007 Sep;13(9):1070-7. Epub 2007 Sep 2.

PMID:
17767167
2.

Moesin expression is a marker of basal breast carcinomas.

Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, Xerri L, Viens P, Birnbaum D, Jacquemier J.

Int J Cancer. 2007 Oct 15;121(8):1779-85.

3.

Molecular definition of breast tumor heterogeneity.

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K.

Cancer Cell. 2007 Mar;11(3):259-73.

4.

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ.

Breast Cancer Res Treat. 2007 Nov;105(3):319-26. Epub 2007 Feb 1.

PMID:
17268817
5.

Understanding ERM proteins--the awesome power of genetics finally brought to bear.

Hughes SC, Fehon RG.

Curr Opin Cell Biol. 2007 Feb;19(1):51-6. Epub 2006 Dec 18. Review.

PMID:
17175152
6.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW.

Cancer Cell. 2006 Dec;10(6):515-27.

7.

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9. Epub 2006 May 26.

8.

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.

MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM.

Cancer Res. 2005 Dec 15;65(24):11265-70.

9.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

10.

Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.

Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K.

Clin Cancer Res. 2005 Nov 15;11(22):8006-14.

11.

Gene expression profiling of breast cell lines identifies potential new basal markers.

Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F.

Oncogene. 2006 Apr 6;25(15):2273-84.

PMID:
16288205
12.

Multiple roles for the receptor tyrosine kinase axl in tumor formation.

Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nör JE, Payan DG, Lorens JB.

Cancer Res. 2005 Oct 15;65(20):9294-303.

13.

Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

Brenton JD, Carey LA, Ahmed AA, Caldas C.

J Clin Oncol. 2005 Oct 10;23(29):7350-60. Epub 2005 Sep 6. Review.

PMID:
16145060
15.

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.

Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A.

J Biol Chem. 2005 Jan 21;280(3):2205-12. Epub 2004 Nov 1.

16.

Bioconductor: open software development for computational biology and bioinformatics.

Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J.

Genome Biol. 2004;5(10):R80. Epub 2004 Sep 15.

17.
18.

Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H.

Lab Invest. 2002 Nov;82(11):1525-33.

PMID:
12429812
19.

Targeting death and decoy receptors of the tumour-necrosis factor superfamily.

Ashkenazi A.

Nat Rev Cancer. 2002 Jun;2(6):420-30. Review. No abstract available.

PMID:
12189384
20.

Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis.

Park SY, Seol DW.

Biochem Biophys Res Commun. 2002 Jul 12;295(2):515-8.

PMID:
12150980

Supplemental Content

Support Center